Sort
40,608 grants matching “prostate cancer”
Prostate Section
$555,067Peter Pinto · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
15-Hydroxyprostaglandin Dehydrogenase, NSAIDs, Vitamin D, and Coloretcal Neoplasi
$554,959Li Li · Case Western Reserve University · U01 · FY2016 · CA
NANOG AS A CRITICAL PROSTATE CANCER (STEM CELL) SELF-RENEWAL GENE
$554,922The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2008 · Department of Defense
Decision Navigation for Advanced Prostate Cancer Treatment Options using mHealth
$554,908Randy Allen Jones · University Of Virginia · R01 · FY2019 · NR
Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma
$554,891Keith D Robertson · Mayo Clinic Rochester · R01 · FY2023 · CA
A proteomic approach for early diagnosis of diabetes
$554,825Julian D Watts · Institute For Systems Biology · R33 · FY2008 · DK
POPULATION BASED STUDIES OF BRCA1
$554,648Dana-Farber Cancer Institute · R01 · FY2001 · CA
Statistical Methods for Genetic Epidemiology
$554,648Alice S Whittemore · Stanford University · R01 · FY2006 · CA
Global genetic and epigenetic approaches to progression of PCa
$554,614Wennuan Liu · Wake Forest University Health Sciences · R01 · FY2010 · CA
CHEMOPREVENTION OF PROSTATE CANCER IN MUTANT MICE: TARGETING THE ANDROGEN RECEPTOR SIGNALING PATHWAY
$554,614The Trustees Of Columbia University In The City Of New York · · FY2008 · Department of Defense
EPINEPHRINE-INDUCED AND ANTIAPOPTOTIC SIGNALING IN PROSTATE CANCER
$554,588Wake Forest University Health Sciences · · FY2008 · Department of Defense
Role of Novel Cytokine-like Molecule Secretoglobin (SCGB) 3A2 in Lung
$554,547Shioko Kimura · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
REDOX STRESS-MEDIATED INAPPROPRIATE ANDROGEN RECEPTOR ELEVATION AS A NOVEL TREATMENT PARADIGM FOR CASTRATION-RESISTANT PROSTATE CANCER
$554,424University Of Miami · · FY2016 · Department of the Army
Genetic and Pharmacogenetic Modifiers of Cancer Risk and Intervention Outcomes
$554,334Mark H Greene · Division Of Cancer Epidemiology And Genetics · ZIA · FY2012 · CA
10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer
$554,265Daniel A Barocas · Vanderbilt University Medical Center · R01 · FY2023 · CA
THE SEMA3E-PLEXIN D1-NRP2 TRIAD IN ENZALUTAMIDE RESISTANCE AND NEUROENDOCRINE PROSTATE CANCER
$554,219Washington State University · · FY2019 · Defense Health Agency
Discovery of a novel MDM2-tubulin signaling pathway as a therapeutic target in AML
$554,143Muxiang Zhou · Emory University · R01 · FY2024 · CA
Adaptive Percutaneous Prostate Interventions using Sensorized Needle
$554,061Junichi Tokuda · Brigham And Women'S Hospital · R01 · FY2021 · CA
Targeting the p110beta isoform of PI3 kinase in prostate cancer
$554,053Thomas M Roberts · Dana-Farber Cancer Inst · R01 · FY2015 · CA
Targeting the p110beta isoform of PI3 kinase in prostate cancer
$554,053Thomas M Roberts · Dana-Farber Cancer Inst · R01 · FY2016 · CA
Targeting the p110beta isoform of PI3 kinase in prostate cancer
$554,053Thomas M Roberts · Dana-Farber Cancer Inst · R01 · FY2018 · CA
Targeting the p110beta isoform of PI3 kinase in prostate cancer
$554,053Thomas M Roberts · Dana-Farber Cancer Inst · R01 · FY2017 · CA
INFRASRUCTURE SUPPORT AND DATA ENHANCEMENTS FOR THE CARET BIOREPOSITORY
$554,050Gary E Goodman · Fred Hutchinson Cancer Research Center · UM1 · FY2015 · CA
MR Fingerprinting and Computerized Decision Support for Prostate Cancer
$554,035Vikas Gulani · Case Western Reserve University · R01 · FY2017 · CA
Core A: Pathobiology Core
$553,798Massimo F Loda · Columbia University Health Sciences · P01 · FY2022 · CA